Research Article

Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex

Maddukuri Sravya,1 Rajamanickam Deveswaran,1 Srinivasan Bharath,1 Basappa Veerbadraiah Basavaraj,1 and Varadharajan Madhavan2

1 Department of Pharmaceutics, M.S. Ramaiah College of Pharmacy, Bangalore 54, India
2 Department of Pharmacognosy, M.S. Ramaiah College of Pharmacy, Bangalore 54, India

Correspondence should be addressed to Rajamanickam Deveswaran; devsmdu@yahoo.com

Received 30 January 2013; Revised 24 August 2013; Accepted 24 August 2013

Academic Editor: Giuseppina De Simone

Copyright © 2013 Maddukuri Sravya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this study was to investigate the use of inclusion complexation technique employing β-cyclodextrin in improving the dissolution profile of candesartan cilexetil, a BCS class-II drug, and to formulate the inclusion complex into orodispersible tablets. The inclusion complexes were formed by physical mixing, kneading, coevaporation, and lyophilisation methods. Inclusion complexes were characterized by FTIR, DSC, XRD, NMR, and mass spectral studies. Inclusion complexes prepared using kneading, and lyophilisation techniques in the molar ratio 1:5 with β-cyclodextrin were used for formulating orodispersible tablets by direct compression with different superdisintegrants like croscarmellose sodium, crospovidone, sodium starch glycolate, and low substituted hydroxypropyl cellulose in varying concentrations. The directly compressible powder was evaluated for precompression parameters, and the prepared orodispersible tablets were evaluated for postcompression parameters. Drug-excipient compatibility studies showed no interaction, and characterization proved the formation of inclusion complex. In vitro disintegration time was found to be within 3 minutes, and all the formulations showed complete drug release of 100% within 20 minutes. The optimized formulation was found to be stable after 6 months and showed no significant change in drug content. This work proved β-cyclodextrins to be effective solubilizing agent in improving the solubility of poorly water soluble drugs.

1. Introduction

Any drug from a given dosage form to be absorbed must be present in the form of solution at the site of absorption. Low aqueous solubility is one of the major problems encountered during formulation development of new chemical entities especially in the process of generic product development. More than 40% of new chemical entities developed in pharmaceutical industry are practically insoluble in water. Various techniques are used for the enhancement of the solubility of poorly soluble drugs including physical and chemical modifications of drug like particle size reduction, crystal engineering, salt formation, solid dispersion, use of surfactant, hydrodropixy, cosolvency, use of surfactants, and complexation [1]. Inclusion complexes are formed by the insertion of the nonpolar molecule or the nonpolar region of one molecule into the cavity of another molecule or host molecules. The most commonly used host molecules are cyclodextrins. Cyclodextrins are nonreducing, crystalline, water soluble, cyclic oligosaccharides consisting of glucose monomers arranged in a donut-shaped ring having hydrophobic cavity and hydrophilic outer surface. Three naturally occurring CDs are α-, β-, and γ-cyclodextrins. Cyclodextrins consist of six, seven, and eight D-glucose units, respectively, attached by α-1, 4-linkages. Cyclodextrins consist of (α-1,4)-linked α-D-glucopyranose units and contain a somewhat lipophilic central cavity and a hydrophilic outer surface. Due to the chair conformation of the glucopyranose units, the cyclodextrins are shaped like a truncated cone [2]. In aqueous solutions, cyclodextrins are able to form inclusion complexes with many drugs by taking up a drug molecule or more frequently some lipophilic moiety of the molecule, into
the central cavity. No covalent bonds are formed or broken during the complex formation, and drug molecules in the complex are in rapid equilibrium with free molecules in the solution.

For the inclusion complex formation, different methods were employed such as physical mixture, kneading, coevaporation, and lyophilisation techniques. The concept of a mouth dissolving drug delivery system emerged from the desire to provide patient with more conventional means of taking their medication. It is difficult for many patients to swallow tablets. Hence, they do not comply with prescription, which results in high incidence of noncompliance and ineffective therapy. A mouth-dissolving drug delivery system, in most cases, is a tablet that dissolves or disintegrants in the oral cavity without the need of water or chewing [3]. Candesartan cilexetil is an angiotensin-II receptor antagonist used mainly for the treatment of hypertension. It is sparingly soluble in water belonging to BCS class-II, and its half-life is 5.1 h with oral bioavailability of 15% [4]. Therefore, in this present study, an attempt was made to formulate candesartan cilexetil, a poorly water soluble BCS class-II antihypertensive drug into an orodispersible tablet by forming an inclusion complex with an inert cyclic macromolecule \( \beta \)-cyclodextrins.

2. Materials and Methods

2.1. Materials. Candesartan cilexetil was a gift sample from Hetero Drugs Pvt. Ltd. (Hyderabad). \( \beta \)-Cyclodextrin (\( \beta \)-CD) was obtained from S D Fine-Chem. Ltd. (Mumbai, India). Crospovidone, croscarmellose sodium, and low substituted hydroxypropyl cellulose were obtained from Yarrow Chemicals India Pvt. Ltd. (Mumbai, India). Mannitol was obtained from Thermo Fischer Scientific India Pvt. Ltd. (Mumbai, India). Sodium starch glycolate was obtained from E. Merck Ltd. (Mumbai, India). Methanol was obtained from RFCL Ltd. (New Delhi, India). All other ingredients used were of analytical grade.

2.2. Preparation of Cyclodextrin Inclusion Complexes [5]

2.2.1. Physical Mixture. The physical mixture of candesartan cilexetil with \( \beta \)-CD was prepared by mixing candesartan cilexetil with \( \beta \)-CD in a mortar and pestle. Mixing was continued for one hour with constant trituration and then passed through sieve no. 100. The resulting sample was stored in a desiccator until further use. The physical mixture was prepared in 1:1, 1:3, and 1:5 molar ratios.

2.2.2. Kneading Method. \( \beta \)-CD was taken in a mortar, and 10 mL of 50% ethanol was added and triturated to get slurry. Then, slowly drug was incorporated into the slurry, and trituration was further continued for one hour. Slurry was then air-dried at 25°C for 24 hours, pulverized, and passed through sieve no. 100. The resulting sample was stored in a desiccator until further use. Candesartan cilexetil complexes with \( \beta \)-CD were prepared in 1:1, 1:3, and 1:5 molar ratios.

2.2.3. Coevaporation. Inclusion complex was prepared by dissolving 1:1, 1:3, and 1:5 molar ratios of \( \beta \)-CD and candesartan cilexetil in 10 mL of 50% aqueous ethanol. The solution was stirred till a clear solution was obtained, and the resulting solution was evaporated under vacuum at a temperature of 45°C. The solid residue was further dried completely at 45°C for 48 h. The dried complex was pulverized into a fine powder and sieved through sieve no. 100. The resulting sample was stored in a desiccator until further use.

2.2.4. Freeze-Drying. Candesartan cilexetil and \( \beta \)-CD in molar quantities of 1:1, 1:3, and 1:5 were taken separately in 20 mL of water and mixed thoroughly using a magnetic stirrer. The resultant solution was frozen in a deep freezer at \(-20°C\) for about 12 h. The frozen mixture was then freeze-dried in the freeze-dryer for 8 h at \(-50°C\) under vacuum. The resultant product was stored in a desiccator.

2.3. Characterization of Complexes [6]

2.3.1. Phase Solubility Studies. Phase solubility studies were carried out according to the method reported by Higuchi and Connors. An excess of candesartan cilexetil was added to 10 mL portions of distilled water, each containing variable amount of \( \beta \)-CD such as 0, 2, 4, 6, 8, and 10 millimoles/liter. All the solutions were shaken in rotary shaker for 72 hours. The solutions were filtered, and their absorbance was measured at 255.5 nm [7]. The apparent stability constants (1:1) were calculated from the phase solubility diagrams, according to the following equation:

\[
K_c = \frac{\text{slope}}{S_0 (1 - \text{slope})},
\]

where \( K_c \) = apparent stability constant and \( S_0 \) = intercept.

2.3.2. Drug Content Estimation. 100 mg of drug \( \beta \)-CD inclusion complex was accurately weighed and transferred to 100 mL volumetric flask. To this, 50 mL of 5% PEG 400 solution and 50 mL of distilled water were added. The resulting solution was diluted suitably, and drug content was estimated spectrophotometrically (Shimadzu, Japan, UV-1701) at 232 nm using distilled water as blank. The drug content was calculated using calibration curve.

2.3.3. X-Ray Diffractometry (XRD). The XRD patterns of drug, \( \beta \)-cyclodextrin, and complexes were recorded by using Philips Holland-PW 1710 scanner with filter Cu radiation over the interval 5–60°/2θ. The operation data were as follows: voltage 35 kV, current 20 mA, filter Cu, and scanning speed 1°/min.

2.3.4. \( ^1H \) Nuclear Magnetic Resonance and Mass Spectroscopy Studies. \( ^1H \) nuclear magnetic resonance spectra were recorded on AMX400 NMR spectrometer. Chemical shifts (δ) are reported in parts per million downfield from internal reference standard tetramethylsilane [8]. Mass spectra were recorded on ESI-MS, Shimadzu, Japan, and molecular weight analysis was carried out [9].
2.3. In Vitro Dissolution Studies. In vitro dissolution of candesartan inclusion complexes were studied in USP type II dissolution apparatus using 900 mL of distilled water as dissolution medium at 75 rpm and a temperature of 37 ± 0.5°C. Complex equivalent to 8 mg of candesartan was used in each test. 5 mL of sample of dissolution medium was withdrawn at suitable time intervals, diluted suitably, and analyzed by measuring the absorbance at 255.5 nm. The volume withdrawn at each time interval was replaced with fresh quantity of dissolution medium to maintain sink conditions. The amount of candesartan released was calculated and plotted against time and compared with pure drug.

2.4. Formulation of Orodispersible Tablets of Candesartan-β-Cyclodextrin Complexes. Candesartan-β-cyclodextrin complex, mannitol, low substituted hydroxy propyl cellulose, crospovidone, croscarmellose sodium, sodium starch glycolate, aspartame, aerosol, and talc were weighed and passed through no. 60 mesh separately. Then, the ingredients were mixed thoroughly and compressed into tablets using 6 mm punches in rotary tablet press (Rīmēk RSB-4 Minipress, Cadmach). Formulations of candesartan cilexetil-β-cyclodextrin complex orodispersible tablets by direct compression method are shown in Table 1.

2.5. Precompression Parameters. The prepared granules were evaluated for angle of repose, bulk density, tapped density, Hausner's ratio, and Carr’s compressibility index [10, 11].

2.6. Postcompression Parameters of Orodispersible Tablets [12]

2.6.1. Weight Variation. Twenty tablets were selected at random and individually weighed, and the average weight was calculated. The uniformity of weight was determined according to pharmacopoeial specifications.

2.6.2. Hardness and Friability. Hardness is the tensile strength of tablets expressed in kg/cm², which was determined using Monsanto hardness tester. Preweighed sample of tablets was placed in the friabilator (Roche Friabilator) and operated for 100 revolutions. Tablets were dusted and reweighed.

Percentage friability was calculated by using the formula

\[ F = \frac{W_{\text{initial}} - W_{\text{final}}}{W_{\text{initial}}} \times 100, \]

where \( W_{\text{initial}} \) = initial weight of 20 tablets and \( W_{\text{final}} \) = final weight of 20 tablets.

2.6.3. Drug Content. Five tablets from each formulation were selected randomly, crushed and mixed. From the mixture powder equivalent to 10 mg of candesartan, cilexetil was weighed and dissolved in 100 mL of 5% PEG 400 in distilled water. The resulting solution was filtered through Whatman filter paper no. 41, diluted suitably, and the absorbance of the resulting solution was measured spectrophotometrically at 232 nm using distilled water as blank. Experiments were carried out thrice, and average percentage drug content was considered.

Drug content was estimated by the formula

\[ \text{Drug content} = \frac{\text{concentration} \times \text{dilution factor}}{1000}, \]

\[ \% \text{Drug content} = \frac{\text{Practical yield}}{\text{Theoretical yield}} \times 100. \]

2.6.4. In Vitro Dispersion Time [13, 14]. In vitro dispersion time was measured by dropping tablets in a 10 mL measuring cylinder containing 6 mL of buffer solution simulating saliva fluid (pH 7.4). The time for the tablet to completely disintegrate into fine particles was noted. Six tablets from each formulation were randomly, selected and In vitro dispersion time was noted.

2.6.5. In Vitro Disintegration Time. The disintegration time for all formulations was carried out using tablet disintegration test apparatus. Six tablets were placed individually in each tube of disintegration test apparatus, and discs were placed. The water was maintained at a temperature of 37 ± 2°C, and time taken for the entire tablet to disintegrate completely was noted.

2.6.6. Wetting Time and Water Absorption Ratio. A tablet is placed on piece of tissue paper that was folded twice and kept in a petri dish (internal diameter = 6.5 cm) containing 6 mL of water, and the time for complete wetting is measured. The wetted tablet is then weighed, and the water absorption ratio, \( R \), is determined using following equation:

\[ R = \frac{100 (W_a - W_b)}{W_b}, \]

where \( W_a \) and \( W_b \) are the weights of tablet before and after water absorption, respectively.

2.6.7. In Vitro Drug Release. In vitro drug release studies were carried out using 900 mL of distilled water as dissolution medium in USP dissolution apparatus type II rotating paddle apparatus. The rotating speed was maintained at 75 rpm, and temperature was maintained at 37°C ± 0.5°C. 5 mL of solution was withdrawn at regular predetermined time intervals, and same volume of sample was replaced with fresh dissolution medium. The samples were diluted suitable and the absorbances of the resulting solution were measured at 255.5 nm using UV/Visible spectrophotometer (UV-1601, Shimadzu, Japan). All the experiments were carried out in triplicate.

2.6.8. Stability Study. The selected formulations were closely packed in aluminum foils and then stored at 40°C ± 2°C/75% RH ± 5% in stability chamber for 6 months and evaluated for their physical appearance, drug content, percent friability, and in vitro disintegration time at intervals of 2 months [15].
Table 1: Formulation table for ODT’s using complexes prepared by kneading method.

| Formulations | Ingredients (mg) | Total tablet weight = 150 mg |
|--------------|-----------------|-----------------------------|
|              | Ingredients     |                             |
| F1           | 82              | 49                          |
| F2           | 82              | 46.5                        |
| F3           | 82              | 44                          |
| F4           | 82              | 49                          |
| F5           | 82              | 46.5                        |
| F6           | 82              | 44                          |
| F7           | 82              | 49                          |
| F8           | 82              | 46.5                        |
| F9           | 82              | 44                          |
| F10          | 82              | 49                          |
| F11          | 82              | 46.5                        |
| F12          | 82              | 44                          |

3. Results and Discussion

All the complexes were subjected to in vitro dissolution study, and complexes prepared by kneading method and freeze-drying method in the molar ratio of 1:5 were used for further study. The drug content of all the candesartan cilexetil-β-cyclodextrin complexes was found to be 98.4%–99.9%.

3.1. FTIR Studies. FTIR was performed for the pure drug β-cyclodextrin and its physical mixture to detect any sign of interaction which would be reflected by a change in the position or disappearance of any characteristic peaks of the compound. The IR spectra of the pure candesartan cilexetil (Figure 1) showed characteristic peaks which are shown in Table 7. The IR spectra of the inclusion complexes prepared by kneading and lyophilisation methods showed the presence of characteristic peaks at the corresponding wave numbers of both pure candesartan cilexetil and β-cyclodextrin, thereby confirming the formation of an inclusion complex. The IR spectra of inclusion complexes along with the excipients used in the tablet formulation showed neither shift nor disappearance of characteristic peaks suggesting that there was no interaction between drug and β-Cyclodextrin.

3.2. Differential Scanning Calorimetry. One of the most classic applications of DSC analysis is the determination of the possible interactions between a drug entity and the excipients in its formulations. When guest molecules are included in CD cavities, their melting, boiling, glass transition, and sublimation points shift to different temperatures or disappear. Figures 2(a)–2(e) revealed the thermal behaviors of the pure components together with excipients. Candesartan cilexetil peaks are clear in its DSC thermogram (Figure 2(a)) demonstrating a sharp characteristic endothermic peak at 172.06°C, which is within its melting temperature range (Tm); such endothermic peak signifies that candesartan cilexetil used was in pure crystalline state. β-cyclodextrins peaks are distinct in Figure 2(b) demonstrating a broad characteristic endothermic peak at 222°C, which is within its melting range; such endothermic peak signifies that β-cyclodextrin was in pure crystalline state. DSC thermogram of the physical mixture of candesartan cilexetil with β-cyclodextrin (Figure 2(c)) demonstrated the presence of two endothermic peaks, both at melting range of candesartan cilexetil and β-cyclodextrin indicating not much interaction between them. DSC thermograms of inclusion complexes prepared by kneading and lyophilisation techniques (Figures 2(d) and 2(e)) showed distinct exothermic peaks at melting range of candesartan cilexetil and β-cyclodextrin, indicating the change in nature from crystalline to amorphous form. This change in nature from crystalline to amorphous form might be the reason for the enhanced solubility.

3.3. Characterization of Prepared Candesartan Cilexetil-β-Cyclodextrin Complexes. Inclusion complexes between candesartan cilexetil and β-cyclodextrin were prepared by physical mixture, kneading method, coprecipitation method, and lyophilisation method in the molar ratios of 1:1, 1:3, and 1:5. A total of 12 trial formulations has been prepared and evaluated for improvement in solubility of candesartan cilexetil. The most efficient preparation methods for inclusion complexes have been proven to be the lyophilisation method and kneading method, while the coprecipitation method is characterized by a lower reaction output due to the filtration step. All further studies have been performed on inclusion complexes prepared by lyophilisation method and kneading method in the molar ratio of 1:5 due to its improved solubility.

3.4. Phase Solubility Studies. Analyzing the phase solubility profiles, it was observed that the increase of candesartan cilexetil solubility in the system was due to due to molecular interaction with β-CD (Figure 3). Candesartan cilexetil formed soluble complexes with β-CD in water showing a
typical AL-type solubility diagrams where the regression coefficient of the curve and inclusion stability constant ($K_c$) calculated according to equation were found to be 0.9867 and 0.04848 M$^{-1}$. When the complex is first order with respect to ligand and first or higher order with respect to substrate, then AL-type phase solubility profile is obtained. The phase solubility diagram was classified as AL-type indicating the formation of a 1:1 candesartan cilexetil:β-CD inclusion complex. The lower values of the stability constants ($K_c$) suggest that the candesartan cilexetil:β-CD interaction is weak and also that the inclusion process is enthalpically driven and spontaneous [16].

3.5. XRD Studies. The XRD results were in good agreement with the thermal analysis data. X-ray diffraction patterns in Figure 4(a) revealed that pure candesartan cilexetil was clearly in crystalline state as it showed sharp distinct peaks notably at 2θ diffraction angles of 9.97°, 17.04°, 18.74°, 19.40°, 21.63°, 23.94°, 25.16°, 27.96°, and 29.28°. X-ray diffraction pattern in Figure 4(b) revealed that pure β-cyclodextrin was in a crystalline state as it showed sharp distinct peaks at 2θ diffraction angles of 12.4° and 19.0°. X-ray diffraction pattern of inclusion complexes prepared by kneading and lyophilisation techniques (Figures 4(c)-4(d)) showed sharp distinct peaks at 2θ diffraction angles of 12.4°, 19.0°, 17.04°, 18.74°, and 19.40° that are characteristic for both candesartan cilexetil and β-cyclodextrin. The complex formation led to the broadening of the existing peaks, appearance of a few new peaks, and shifting of certain peaks. This could be due to the conversion of crystalline to amorphous form during complexation [17].

3.6. Mass Spectral Studies. Mass spectroscopic studies were carried out to find out the molecular weight of candesartan cilexetil-β-cyclodextrin inclusion complexes prepared by kneading method and lyophilisation technique. From Figure 5(a), inclusion complex prepared by kneading method showed molecular ion peak at 102.05 and 423.18 on m/z scale. Other important fragments obtained were at 299 and 266 on m/z scale. From Figure 5(b), inclusion complex prepared by lyophilisation technique showed similar molecular ion peaks on m/z scale. Other important fragments obtained were at 299 and 148 on m/z scale. Extensive fragmentation seen in mass spectra may be attributed to large molecular weight of candesartan cilexetil and β-cyclodextrin. So based on the above, the molecular weight of the prepared complex was found to be 423.18 Dalton.

3.7. NMR Spectral Studies. The 1H-NMR chemical shift for each proton of candesartan cilexetil and βCD was evaluated for the formation of inclusion complex between candesartan cilexetil and βCD at molar ratio 1:5 of candesartan
cilexetil and βCD. The chemical shifts for different protons in candesartan cilexetil (Figure 6(a)) were seen at 1.2, 2.4, 4.5, 5.5, and 6.8–7.6 ppm. The chemical shifts for different protons in β-cyclodextrins (Figure 6(b)) were seen at 2, 3.2, 3.6, 4.4, 4.8, and 5.8 ppm. The chemical shifts for the protons present in both candesartan cilexetil and β-cyclodextrins were found in inclusion complexes prepared by kneading method and lyophilisation technique (Figures 6(c)-6(d)). Since the complexes which were analysed were prepared using 1:5 molar ratio, the chemical shift values for protons present in candesartan cilexetil were seen in minimal intensity. These minimal intensity chemical shifts seen in inclusion complexes can also be accounted to the inclusion complexation of candesartan cilexetil into the cavity of β-cyclodextrins.

3.8. In Vitro Drug Release Profile. In vitro release studies were carried out using USP type II tablet dissolution test apparatus.
### Table 2: Formulation table for ODT’s using complexes prepared by lyophilisation method.

| Formulations | Candesartan-β-cyclodextrin complex | Mannitol | Low HPC | Crosspovidone | Cross carmelllose sodium | Sodium starch glycolate | Aspartame | Aerosil | Talc |
|--------------|-----------------------------------|----------|---------|---------------|--------------------------|------------------------|-----------|---------|-----|
| F13          | 82                                 | 49       | 5       | —             | —                        | —                      | 5         | 3       | 6   |
| F14          | 82                                 | 46.5     | 7.5     | —             | —                        | —                      | 5         | 3       | 6   |
| F15          | 82                                 | 44       | 10      | —             | —                        | —                      | 5         | 3       | 6   |
| F16          | 82                                 | 49       | —       | 5             | —                        | —                      | 5         | 3       | 6   |
| F17          | 82                                 | 46.5     | —       | 7.5           | —                        | —                      | 5         | 3       | 6   |
| F18          | 82                                 | 44       | —       | 10            | —                        | —                      | 5         | 3       | 6   |
| F19          | 82                                 | 49       | —       | —             | 5                        | —                      | 5         | 3       | 6   |
| F20          | 82                                 | 46.5     | —       | —             | 7.5                      | —                      | 5         | 3       | 6   |
| F21          | 82                                 | 44       | —       | —             | 10                       | —                      | 5         | 3       | 6   |
| F22          | 82                                 | 46.5     | —       | —             | —                        | —                      | 5         | 3       | 6   |
| F23          | 82                                 | 44       | —       | —             | —                        | 7.5                    | 5         | 3       | 6   |
| F24          | 82                                 | 49       | —       | —             | —                        | —                      | 5         | 3       | 6   |

### Table 3: Precompression parameters of prepared granules (F1 to F12).

| Formulation code | Bulk density a (g/mL) | Tapped density a (g/mL) | Hausner’s ratio a | Carr’s index a (%) | Angle of repose a (θ) |
|------------------|-----------------------|-------------------------|-------------------|--------------------|-----------------------|
| F1               | 0.41±0.002            | 0.61±0.002              | 1.51±0.002        | 33.31±0.11         | 18°26’±0.115          |
| F3               | 0.41±0.002            | 0.49±0.002              | 1.25±0.002        | 16.72±0.15         | 22°58’±0.642          |
| F5               | 0.38±0.002            | 0.54±0.002              | 1.44±0.002        | 30.64±0.20         | 26°56’±0.550          |
| F7               | 0.41±0.002            | 0.62±0.002              | 1.50±0.002        | 33.35±0.11         | 25°64’±1.155          |
| F9               | 0.36±0.002            | 0.51±0.002              | 1.40±0.01         | 28.61±0.10         | 30°11’±0.818          |
| F11              | 0.42±0.002            | 0.56±0.002              | 1.33±0.002        | 25.04±0.20         | 25°92’±1.601          |
| F13              | 0.42±0.002            | 0.56±0.002              | 1.33±0.002        | 25.08±0.11         | 22°78’±4.215          |
| F15              | 0.38±0.002            | 0.55±0.002              | 1.33±0.001        | 25.08±0.15         | 26°56’±1.172          |
| F17              | 0.38±0.002            | 0.55±0.002              | 1.44±0.01         | 30.72±0.15         | 27°47’±0.692          |
| F19              | 0.41±0.002            | 0.54±0.002              | 1.33±0.01         | 24.91±0.05         | 23°74’±0.642          |
| F21              | 0.41±0.002            | 0.62±0.002              | 1.50±0.01         | 33.37±0.15         | 22°78’±0.692          |

| Formulation code | Bulk density a (g/mL) | Tapped density a (g/mL) | Hausner’s ratio a | Carr’s index a (%) | Angle of repose a (θ) |
|------------------|-----------------------|-------------------------|-------------------|--------------------|-----------------------|
| F13              | 0.41±0.002            | 0.49±0.002              | 1.25±0.002        | 16.73±0.11         | 22°58’±0.115          |
| F14              | 0.36±0.002            | 0.56±0.002              | 1.55±0.002        | 35.64±0.15         | 20°31’±0.642          |
| F15              | 0.42±0.002            | 0.56±0.002              | 1.33±0.002        | 25.04±0.20         | 21°80’±0.550          |
| F16              | 0.42±0.002            | 0.56±0.002              | 1.33±0.002        | 25.08±0.11         | 25°64’±1.155          |
| F17              | 0.38±0.002            | 0.55±0.002              | 1.44±0.01         | 30.74±0.10         | 30°11’±0.818          |
| F18              | 0.41±0.002            | 0.54±0.002              | 1.33±0.01         | 24.92±0.05         | 22°78’±0.346          |
| F19              | 0.41±0.002            | 0.62±0.002              | 1.50±0.01         | 33.31±0.15         | 23°26’±1.601          |
| F20              | 0.38±0.002            | 0.54±0.002              | 1.44±0.02         | 30.65±0.20         | 19°29’±4.215          |
| F21              | 0.36±0.002            | 0.56±0.002              | 1.55±0.01         | 35.63±0.15         | 27°47’±1.172          |
| F22              | 0.41±0.002            | 0.62±0.002              | 1.50±0.01         | 33.34±0.15         | 26°56’±0.692          |
| F23              | 0.42±0.002            | 0.63±0.002              | 1.53±0.01         | 33.36±0.05         | 18°77’±0.642          |
| F24              | 0.41±0.002            | 0.54±0.002              | 1.33±0.01         | 24.90±0.15         | 22°14’±0.692          |

*Mean ± S.D (n = 3).*
Table 5: Postcompression parameters for prepared orodispersible tablets.

| Formulation code | Weight variation a (mg) | Friability a (%) | Hardness a (kg/cm²) | Percentage drug content a |
|------------------|-------------------------|------------------|---------------------|--------------------------|
| F₁               | 140 ± 2.58              | 0.66 ± 0.01      | 5.1 ± 0.12          | 99.4 ± 0.68              |
| F₂               | 150 ± 2.65              | 0.67 ± 0.01      | 5.1 ± 0.05          | 99.8 ± 1.00              |
| F₃               | 150 ± 1.10              | 0.67 ± 0.01      | 5.2 ± 0.11          | 100.15 ± 1.00            |
| F₄               | 150 ± 2.58              | 0.66 ± 0.01      | 4.6 ± 0.11          | 98.66 ± 1.15             |
| F₅               | 150 ± 2.58              | 0.66 ± 0.01      | 5.2 ± 0.12          | 98.14 ± 1.15             |
| F₆               | 140 ± 2.66              | 0.67 ± 0.01      | 4.8 ± 0.05          | 99.71 ± 2.11             |
| F₇               | 154 ± 2.47              | 0.66 ± 0.05      | 5.5 ± 0.11          | 99.9 ± 0.92              |
| F₈               | 140 ± 2.70              | 0.66 ± 0.01      | 5.4 ± 0.05          | 100.15 ± 1.66            |
| F₉               | 156 ± 2.10              | 0.66 ± 0.02      | 5.2 ± 0.05          | 99.52 ± 1.15             |
| F₁₀              | 155 ± 4.10              | 0.67 ± 0.01      | 5.4 ± 0.01          | 100.28 ± 1.61            |
| F₁₁              | 157 ± 2.10              | 0.66 ± 0.05      | 4.2 ± 0.11          | 100.1 ± 0.69             |
| F₁₂              | 140 ± 4.10              | 0.66 ± 0.01      | 5.4 ± 0.01          | 98.66 ± 1.61             |
| F₁₃              | 150 ± 2.10              | 0.67 ± 0.05      | 4.7 ± 0.11          | 99.04 ± 1.61             |
| F₁₄              | 150 ± 2.45              | 0.66 ± 0.05      | 5.3 ± 0.16          | 99.23 ± 1.61             |
| F₁₅              | 140 ± 2.45              | 0.67 ± 0.01      | 5.3 ± 0.16          | 99.33 ± 1.89             |
| F₁₆              | 150 ± 2.67              | 0.66 ± 0.01      | 5.8 ± 0.19          | 99.71 ± 1.67             |
| F₁₇              | 158 ± 2.10              | 0.67 ± 0.01      | 5.4 ± 0.01          | 99.9 ± 1.61              |
| F₁₈              | 140 ± 4.10              | 0.66 ± 0.05      | 4.8 ± 0.11          | 100.3 ± 1.61             |
| F₁₉              | 150 ± 2.10              | 0.67 ± 0.01      | 5.5 ± 0.01          | 100.09 ± 1.89            |
| F₂₀              | 150 ± 2.45              | 0.66 ± 0.05      | 4.8 ± 0.11          | 100.28 ± 1.67            |
| F₂₁              | 140 ± 2.45              | 0.67 ± 0.05      | 5.6 ± 0.16          | 99.9 ± 1.15              |
| F₂₂              | 150 ± 2.67              | 0.66 ± 0.01      | 5.2 ± 0.16          | 99.71 ± 1.61             |
| F₂₃              | 150 ± 2.10              | 0.66 ± 0.01      | 5.8 ± 0.19          | 99.61 ± 0.69             |
| F₂₄              | 150 ± 2.45              | 0.67 ± 0.05      | 5.1 ± 0.19          | 99.52 ± 1.15             |

*Mean ± S.D (n = 3).

3.9. Formulation of Candesartan Cilexetil-β-Cyclodextrin Orodispersible Tablets. Candesartan cilexetil-β-cyclodextrin inclusion complexes prepared by kneading method and lyophilisation technique at molar ratio 1:5 were selected for formulating into orodispersible tablets. Each complex was formulated into 12 formulations using four superdisintegrants, each of which is in three different concentrations as shown in Tables 1 and 2.

3.10. Characterization of Prepared Orodispersible Tablet Formulation

3.10.1. Flow Properties. The precompression parameters for all the 24 formulations were carried out, and the results were shown in Tables 3 and 4. The bulk density of all 24 formulations ranged between 0.361 and 0.421 g/mL, and tapped density ranged from 0.46 and 0.63 g/mL. Hausner’s ratio with values less than 1.5 indicates good flow property. Carr’s index value was between the range 16.7 and 35.6%.
which confirmed that all 24 formulations are showing good flow properties and good compressibility. The angle of repose was found to be from 18° to 31°, thereby confirming the good flow property of the granules. All the parameters were within the acceptable limits for powder blend with good flow properties while compressing the tablets.

3.10.2. Weight Variation Test. The weights of all tablet formulations ranged between 137 and 161 mg (Table 5). As the weight of tablets was 150 mg, and the acceptable weight variation range was between 138.75 mg and 161.25 mg (±7.5%). It was observed that all the tablet formulations were within the pharmacopoeial limits.

3.10.3. Hardness. The hardness of all formulations was determined, and the results were shown in Table 5. The values of hardness were found to be in the range of 4.2 to 5.8 kg/cm².

3.10.4. Friability. The percentage friability of all the formulations was found to be not more than 0.7%, which is well within the limit of less than 1%. The results of friability indicated that the tablets were mechanically stable.

3.10.5. Drug Content. The drug content studies for all 24 formulations were carried out by a validated method using 5% PEG 400 in distilled water and was found to be in the range of 98.14%–100.28% of candesartan cilexetil, and the results were shown in Table 5.

3.10.6. Wetting Time and Water Absorption Ratio. Wetting time of the formulations was determined, and all the formulations showed wetting time of 90 to 210 seconds. Water absorption ratio of all the formulations was calculated using the equation, and all the formulations showed good water absorption ratio from 72.58 to 81.42. Wetting time of the dosage form is related to contact angle. Lower wetting time implies a quicker disintegration time (Table 6).

3.10.7. In Vitro Dispersion Time. In vitro dispersion time of all the formulations of orodispersible tablets was determined and was found to be 66 to 184 seconds. Formulations F₁₂ and F₂₄ showed good in vitro dispersion time of 94 and 66 seconds, respectively.

3.10.8. In Vitro Disintegration Time. In vitro disintegration time of formulations F₁ to F₂₄ was determined, and all the formulations showed disintegration time within three seconds. According to the European pharmacopoeia, the fast
3.10.9. In Vitro Drug Release Profile. The prepared orodispersible tablets were evaluated for their in vitro drug release profiles. Formulations F_1 to F_{12} were prepared using complexes prepared by kneading method, and formulations F_{13} to F_{24} were prepared using complexes prepared by lyophilisation method. Formulations containing low substituted hydroxyl propyl cellulose as superdisintegrant, namely, F_1, F_2, and F_3, showed 97.8%, 100.01%, and 99.5%, respectively, at the end of 20 minutes, whereas formulations containing crospovidone as superdisintegrant, namely, F_4, F_5, and F_6, showed 95.6%, 97.8%, and 98.9%, respectively, at the end of 20 minutes. Formulations containing croscarmellose sodium as superdisintegrant, namely, F_7, F_8, and F_9, showed 97.7%, 98.8%, and 98.5%, respectively, at the end of 20 minutes, whereas formulations containing sodium starch glycolate as superdisintegrant, namely, F_{10}, F_{11}, and F_{12}, showed 97.8%, 101.9%, and 101.2%, respectively, at the end of 20 minutes. Formulations containing low substituted hydroxyl propyl
cellulose as superdisintegrant, namely, F13, F14, and F15, showed 95.6%, 96.7%, and 98.8%, respectively at the end of 20 minutes, whereas formulations containing crospovidone as superdisintegrant, namely, F16, F17, and F18, showed 97.8%, 99.9%, and 97.7%, respectively, at the end of 20 minutes. Formulations containing croscarmellose sodium as superdisintegrant, namely, F19, F20, and F21, showed 97.7%, 97.8%, and 98.8%, respectively, at the end of 20 minutes, whereas formulations containing sodium starch glycollate as superdisintegrant, namely, F22, F23, and F24, showed 98.9%, 100.9% and 101.1%, respectively at the end of 20 minutes. Formulations F12 and F24 prepared using crospovidone and sodium starch glycollate in the concentration of 8% showed lowest disintegration time of 74 and 68 seconds and highest drug release of 101.12 and 101.14 at the end of 20 minutes. The In vitro drug release study indicated faster and maximum drug release from formulations F12 and F24. The release profiles of formulations F12 and F24 were demonstrated in Figure 7.

3.11. Stability Studies. The accelerated stability studies of orodispersible tablets were performed as per the ICH guidelines to investigate whether the orodispersible tablets are...
4. Conclusion

In the present study, complexes of candesartan cilexetil with β-cyclodextrins in molar ratio of 1:5 were prepared and characterized. These complexes were formulated into orodispensible tablets using varying concentrations of superdisintegrants. Precompression and postcompression parameters were determined, and all the parameters met the requirements. All the tablet formulations showed *in vitro* disintegration time of less than 3 minutes and 100 percent drug releases within 20 minutes. By this study, it can be concluded that β-cyclodextrins can be used as a solubilizing agent to improve solubility of poorly water soluble drugs. The oral bioavailability of the drug could be improved by this methodology by more than two times due to improved aqueous solubility when compared to pure drug. This methodology of inclusion complexation can be further exploited for the successful delivery of poorly water soluble compounds.

Conflict of Interests

The authors report no conflict of interests.

Acknowledgments

The authors wish to thank Gokula Education Foundation, Bangalore, for providing necessary facilities to carry out the research work. The authors wish to thank the Indian Institute of Science (IISc), Bangalore, for carrying out DSC, NMR, and XRD studies.

References

[1] R. Narazaki, T. Harada, N. Takami, Y. Kato, and T. Ohwaki, “A new method for disintegration studies of rapid disintegrating tablet,” *Chemical and Pharmaceutical Bulletin*, vol. 52, no. 6, pp. 704–707, 2004.

[2] Y. Fu, S. Yang, S. H. Jeong, S. Kimura, and K. Park, “Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies,” *Critical Reviews in Therapeutic Drug Carrier Systems*, vol. 21, no. 6, pp. 433–476, 2004.

[3] H. Seager, “Drug-delivery products and the Zydis fast-dissolving dosage form,” *Journal of Pharmacy and Pharmacology*, vol. 50, no. 4, pp. 375–382, 1998.

[4] http://en.wikipedia.org/wiki/candesartancilexetil.

[5] S. Yang, Y. Fu, S. H. Jeong, and K. Park, “Application of poly(acrylic acid) superporous hydrogel microparticles as a super-disintegrant in fast-disintegrating tablets,” *Journal of Pharmacy and Pharmacology*, vol. 56, no. 4, pp. 429–436, 2004.

[6] G. Abdelbary, P. Prinderre, C. Eouani, J. Joachim, J. P. Reynier, and P. Piccerelle, “The preparation of orally disintegrating tablets using a hydrophilic waxy binder,” *International Journal of Pharmaceutics*, vol. 278, no. 2, pp. 423–433, 2004.

[7] P. V. Swamy, S. P. Divate, S. B. Shirsand, and P. Rajendra, “Preparation and evaluation of orodispensible tablets of pheniramine maleate by effervescent method,” *Indian Journal of Pharmaceutical Sciences*, vol. 71, no. 2, pp. 151–154, 2009.

[8] T. Pralhad and K. Rajendrakumar, “Study of freeze-dried quercetin-cyclodextrin binary systems by DSC, FT-IR, X-ray affect during storage conditions. Optimized formulations F_{12} and F_{24} were kept at 40 ± 2°C with 75 ± 5% RH for a period of 6 months. The physical appearances, friability, disintegration time, and drug content were measured for these tablets at the end of 2, 4, and 6 months. The results showed that there was no significant difference between the initial and aged orodispensible tablets. The percentage drug content and friability were found to be 96.1 and 0.81% for formulation F_{12} and 96.3 and 0.88% for formulation F_{24} at the end of 6 months. This indicated that the physicochemical parameters, disintegration time, and percentage drug content were not affected by aging. The optimized formulations were physically and chemically stable for a period of 6 months at accelerated stability conditions.
diffraction and SEM analysis,” *Journal of Pharmaceutical and Biomedical Analysis*, vol. 34, no. 2, pp. 333–339, 2004.

[9] S. V. Kulkarni, P. R. Kumar, N. Patel, R. B. Someshwara, B. Ramesh, and K. P. Ashok, “Formulation and evaluation of fast disintegrating Meloxicam tablets and its comparison with marketed product,” *International Journal of Pharmacy and Pharmaceutical Sciences*, vol. 3, no. 1, pp. 91–93, 2011.

[10] S. Schiermeier and P. C. Schmidt, “Fast dispersible ibuprofen tablets,” *European Journal of Pharmaceutical Sciences*, vol. 15, no. 3, pp. 295–305, 2002.

[11] Y. Okuda, Y. Irisawa, K. Okimoto, T. Osawa, and S. Yamashita, “A new formulation for orally disintegrating tablets using a suspension spray-coating method,” *International Journal of Pharmaceutics*, vol. 382, no. 1-2, pp. 80–87, 2009.

[12] H. K. Ibrahim and D. A. El-Setouhy, “Valsartan orodispensible tablets: formulation, in vitro/in vivo characterization,” *AAPS PharmSciTech*, vol. 11, no. 1, pp. 189–196, 2010.

[13] T. Sushma, A. Y. Khan, R. K. Khar, F. J. Ahmad, and Z. Khan, “Development and characterization of paracetamol complexes with hydroxypropyl-β-cyclodextrin,” *Iranian Journal of Pharmaceutical Research*, vol. 6, no. 2, pp. 95–99, 2007.

[14] N. H. Indurwade, T. H. Rajyaguru, and P. D. Nakhat, “Novel approach-fast dissolving tablets,” *Indian Drugs*, vol. 39, no. 8, pp. 405–409, 2002.

[15] Y. Kuno, M. Kojima, S. Ando, and H. Nakagami, “Evaluation of rapidly disintegrating tablets manufactured by phase transition of sugar alcohols,” *Journal of Controlled Release*, vol. 105, no. 1-2, pp. 16–22, 2005.

[16] S. C. Arora, P. K. Sharma, R. Irchhaiya, A. Khatkar, N. Singh, and J. Gagoria, “Development, characterization and solubility study of solid dispersion of cefpodoxime proxetil by solvent evaporation method,” *International Journal of ChemTech Research*, vol. 2, no. 2, pp. 1156–1162, 2010.

[17] L. S. Koester, C. R. Xavier, P. Mayorga, and V. L. Bassani, “Influence of β-cyclodextrin complexation on carbamazepine release from hydroxypropyl methylcellulose matrix tablets,” *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 55, no. 1, pp. 85–91, 2003.